Thalidomide: An option for the pediatric patient with actinic prurigo

Actinic prurigo (AP) is an immune‐mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We repor...

Full description

Saved in:
Bibliographic Details
Published inPediatric dermatology Vol. 37; no. 2; pp. 362 - 365
Main Authors Watts‐Santos, Anabella, Martinez‐Rico, Jessica Carolina, Gomez‐Flores, Minerva, Ocampo‐Candiani, Jorge, Alba‐Rojas, Erika
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2020
Subjects
actinic prurigo
Age Factors
Case reports
Child
Children
Female
Humans
Immunosuppressive Agents - therapeutic use
Medical treatment
Patients
Pediatrics
photodermatosis
photosensitivity
Photosensitivity Disorders - drug therapy
Pruritus
Skin diseases
Skin Diseases, Genetic - drug therapy
Thalidomide
Thalidomide - therapeutic use
thalidomide
photodermatosis
photosensitivity
actinic prurigo
Online AccessGet full text

Cover

More Information
Summary:Actinic prurigo (AP) is an immune‐mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We report the case of a 10‐year‐old girl with AP treated successfully with thalidomide.
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.14086